Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation
New-onset diabetes after transplantation (NODAT) remains a frequent and serious complication after kidney transplantation. We previously reported NODAT in our postkidney transplant population at a frequency of more than 50%, using the definition established by the 2003 International Guidelines. This high rate of posttransplant diabetes has serious negative consequences for future cardiovascular risk and survival after kidney transplant.
Lane, J. T.,
Odegaard, D. E.,
Haire, C. E.,
Collier, D. S.,
Wrenshall, L. E.,
& Stevens, R. B.
(2011). Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation. Transplantation, 92 (10), e56-e57.